Work

A3-adenosine receptors: Design of selective ligands and therapeutic prospects

Year: 1995

Type: article

Abstract: The A3 receptor has been established as a distinct receptor subtype through cloning and the synthesis of selective agonists. The distribution of this subtype in the body is unique and more limited than for A1 or A2 receptors. Actions associated with this subtype include mast cell degranulation, cerebroprotection, cardioprotection, and possibly alteration of fertility. The effects on the inflammatory system and the high level of A3 receptor expression in the lungs suggests the use of A3 antagonists for asthma. Thus, there is a tremendous potential for development for therapeutic purposes of selective drugs, either agonists or antagonists, acting at this receptor.

Source: Drugs of the Future

DOI: 10.1358/dof.1995.020.07.531583

Authors: K.A. Jacobson, H.O. Kim, S.M. Siddiqi, M.E. Olah, G.L. Stiles, D.K.J.E. von Lubitz

Institutions: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Duke Medical Center

Language: English

Topic: Adenosine and Purinergic Signaling

Subfield: Physiology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases